I joined Genentech in 1998 as a Pharmacokinetics Scientist and over the years have held various team and leadership roles leading to my current position as Senior Vice President of Development Sciences. In this role, I am responsible for ensuring the successful translation of promising molecule –discoveries from Research into Development and the effective utilization of development sciences during the clinical phases of drug development. In addition, I am a member of the gRED leadership team, the Development Review committee (DRC), the Research Review committee (RRC) and the Early stage portfolio committee (ESPC). I am also an adjunct faculty at UCSF (Department of Bioengineering and therapeutic Sciences) and at the University of Pacific, Stockton.
I am committed to developing treatments for patients that may significantly improve their lives and am excited to be a part of an organization that continues to be on a mission to really shape the future of medicine. I have had the opportunity to see my individual impact on a number of biologics and small molecules and feel fortunate to work with such a talented and diverse group of passionate people.
Cancer Res.; 68:(22), (2008).
My focus over the last few years has been in ensuring that the quality of the science and technology that Development Sciences brings to the Drug Discovery and Development process is cutting edge and exemplary. I have focused on building a team that not only has the skill sets traditionally required for excelling in drug development such as Safety assessment, Pharmacokinetics, Bioanalytical sciences but also building skill sets that enable our leadership in personalized medicine such as Biomarker development and Diagnostics. Fostering innovation in all of these areas to enable not only our leadership in biologics but also our growth in small molecules and Antibody drug conjugates.